IBDEI0EU ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6385,1,3,0)
 ;;=3^Old MI
 ;;^UTILITY(U,$J,358.3,6385,1,4,0)
 ;;=4^I25.2
 ;;^UTILITY(U,$J,358.3,6385,2)
 ;;=^259884
 ;;^UTILITY(U,$J,358.3,6386,0)
 ;;=Z95.2^^53^409^8
 ;;^UTILITY(U,$J,358.3,6386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6386,1,3,0)
 ;;=3^Presence of Prosthetic Heart Valve
 ;;^UTILITY(U,$J,358.3,6386,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,6386,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,6387,0)
 ;;=Z95.1^^53^409^6
 ;;^UTILITY(U,$J,358.3,6387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6387,1,3,0)
 ;;=3^Presence of Aortocoronary Bypass Graft
 ;;^UTILITY(U,$J,358.3,6387,1,4,0)
 ;;=4^Z95.1
 ;;^UTILITY(U,$J,358.3,6387,2)
 ;;=^5063669
 ;;^UTILITY(U,$J,358.3,6388,0)
 ;;=Z98.61^^53^409^1
 ;;^UTILITY(U,$J,358.3,6388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6388,1,3,0)
 ;;=3^Coronary Angioplasty Status
 ;;^UTILITY(U,$J,358.3,6388,1,4,0)
 ;;=4^Z98.61
 ;;^UTILITY(U,$J,358.3,6388,2)
 ;;=^5063742
 ;;^UTILITY(U,$J,358.3,6389,0)
 ;;=Z95.2^^53^409^9
 ;;^UTILITY(U,$J,358.3,6389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6389,1,3,0)
 ;;=3^Presence of Prosthetic Heart Valve
 ;;^UTILITY(U,$J,358.3,6389,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,6389,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,6390,0)
 ;;=Z95.3^^53^409^10
 ;;^UTILITY(U,$J,358.3,6390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6390,1,3,0)
 ;;=3^Presence of Xenogenic Heart Valve
 ;;^UTILITY(U,$J,358.3,6390,1,4,0)
 ;;=4^Z95.3
 ;;^UTILITY(U,$J,358.3,6390,2)
 ;;=^5063671
 ;;^UTILITY(U,$J,358.3,6391,0)
 ;;=Z95.4^^53^409^7
 ;;^UTILITY(U,$J,358.3,6391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6391,1,3,0)
 ;;=3^Presence of Heart Valve Replacement NEC
 ;;^UTILITY(U,$J,358.3,6391,1,4,0)
 ;;=4^Z95.4
 ;;^UTILITY(U,$J,358.3,6391,2)
 ;;=^5063672
 ;;^UTILITY(U,$J,358.3,6392,0)
 ;;=Z79.01^^53^409^4
 ;;^UTILITY(U,$J,358.3,6392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6392,1,3,0)
 ;;=3^Long Term Current Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,6392,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,6392,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,6393,0)
 ;;=Z83.438^^53^409^3
 ;;^UTILITY(U,$J,358.3,6393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6393,1,3,0)
 ;;=3^Family Hx of Familial Comb Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,6393,1,4,0)
 ;;=4^Z83.438
 ;;^UTILITY(U,$J,358.3,6393,2)
 ;;=^5157632
 ;;^UTILITY(U,$J,358.3,6394,0)
 ;;=Z83.430^^53^409^2
 ;;^UTILITY(U,$J,358.3,6394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6394,1,3,0)
 ;;=3^Family Hx of Elevated Lipoprotein(a)
 ;;^UTILITY(U,$J,358.3,6394,1,4,0)
 ;;=4^Z83.430
 ;;^UTILITY(U,$J,358.3,6394,2)
 ;;=^5157631
 ;;^UTILITY(U,$J,358.3,6395,0)
 ;;=I10.^^53^410^3
 ;;^UTILITY(U,$J,358.3,6395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6395,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,6395,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,6395,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,6396,0)
 ;;=I11.0^^53^410^8
 ;;^UTILITY(U,$J,358.3,6396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6396,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,6396,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,6396,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,6397,0)
 ;;=I11.9^^53^410^9
 ;;^UTILITY(U,$J,358.3,6397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6397,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,6397,1,4,0)
 ;;=4^I11.9
